News

Rumble Boxing teams up with MJFF for Parkinson’s Awareness Month

Rumble Boxing, a U.S. fitness brand, is partnering for the second year with Team Fox, the grassroots fundraising community of The Michael J. Fox Foundation (MJFF), to raise awareness and funds during Parkinson’s Disease Awareness Month this April. Among Rumble’s planned activities is a multicity tour panel…

Trial of VQ-101 for patients with GBA gene mutations begins dosing

The first patient has been dosed in a first-in-human trial testing Vanqua Bio’s VQ-101 as an oral therapy for Parkinson’s disease linked to mutations in the GBA gene, the company has announced. The Phase 1 clinical trial is assessing the safety, tolerability, and pharmacological properties of VQ-101 in both…

Enlarged brain spaces tied to Parkinson’s dyskinesia, per study

A widening of tiny, fluid-filled spaces in certain brain regions could be used as an imaging marker of levodopa-induced dyskinesia (LID) in people with Parkinson’s disease, a study showed. Perivascular spaces, or PVSs, were larger in Parkinson’s patients with LID — a condition in which standard Parkinson’s medications…

NeuroVigil launches portable device to measure brain electrical activity

NeuroVigil has launched its iBrain personal brain monitor — an investigational portable device that can noninvasively record the brain’s electrical activity in people with neurological conditions — in the U.S., according to a company press release. In the second phase of the launch, NeuroVigil will use a smaller…

Phase 2 trial of montelukast oral film starts dosing

The first patients received doses of an oral thin-film formulation of montelukast in a clinical trial testing the treatment’s potential for Parkinson’s disease. The placebo-controlled MONTPARK trial will test how well a high dose of Montelukast VersaFilm, a proprietary formulation being developed by IntelGenx, can slow the progression…